Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANGEL: Rivoceranib in advanced gastric cancer
NCT03042611Phase 3Completed
- Sponsor
- Elevar Therapeutics
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) comparing Rivoceranib Plus BSC with Placebo Plus BSC (2 arms). Primary endpoint: Overall Survival up to 36 months. Started Mar 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03042611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042611.